Eli Lilly and Company's correction may be coming to an end as the actual demand for its drugs seems to be holding well. Learn more about LLY stock here.

Eli Lilly started 2024 on a strong note but struggled during the second half of the year. The drugmaker dealt with several ...

We now have two FDA-approved disease-modifying treatments for Alzheimer's disease, and hundreds of clinical trials are ...

The drug received standard U.S. approval in 2023 after showing it slowed cognitive decline in patients with the brain-wasting ...

Eli Lilly is proving to be an innovative company ... from the U.S. Food and Drug Administration. It also launched Kisunla, one of the few Alzheimer's disease treatments to get the green light ...

“The problem with the Alzheimer’s group is they were very co-opted,” said Peter J. Whitehouse, MD, PhD, a professor of ...

Eli Lilly started 2024 on a strong note but struggled ... from the U.S. Food and Drug Administration. It also launched Kisunla, one of the few Alzheimer's disease treatments to get the green ...